Nextage Therapeutics Ltd
Nextage Therapeutics Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. It offers CellDetect, a diagnostic platform for early cancer detection, including bladder cancer, cervical cancer, and prostate cancer. The company also provides BRONJ Test, a test for bisphosphonate-related osteonecrosis of the jaw. In addition, it offers gene expression, and biomark… Read more
Nextage Therapeutics Ltd (MCTC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2020: -0.224x
Based on the latest financial reports, Nextage Therapeutics Ltd (MCTC) has a cash flow conversion efficiency ratio of -0.224x as of June 2020.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-444.00K) by net assets (ILA1.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nextage Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2013–2019)
This chart illustrates how Nextage Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Nextage Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nextage Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PZ Cussons PLC
LSE:PZC
|
0.034x |
|
DIVIDEND 15 SPLIT A CD 15
F:641
|
N/A |
|
DaikyoNishikawa Corp
F:DK8
|
N/A |
|
HGCAPITAL TRUST LS-025
F:5AC
|
N/A |
|
NGRD3F
SA:NGRD3F
|
N/A |
|
Dividend Select 15 Corp
PINK:DVVDF
|
-0.010x |
|
Bowen Acquisition Corp Rights
NASDAQ:BOWNR
|
N/A |
|
PFERDEWETTEN AG
STU:EMH1
|
-0.669x |
Annual Cash Flow Conversion Efficiency for Nextage Therapeutics Ltd (2013–2019)
The table below shows the annual cash flow conversion efficiency of Nextage Therapeutics Ltd from 2013 to 2019.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2019-12-31 | ILA3.66 Million | ILA-5.00 Million | -1.369x | -145.59% |
| 2018-12-31 | ILA-1.65 Million | ILA-4.95 Million | 3.003x | +334.96% |
| 2017-12-31 | ILA4.44 Million | ILA-5.67 Million | -1.278x | +56.88% |
| 2016-12-31 | ILA2.36 Million | ILA-7.00 Million | -2.964x | -66.62% |
| 2015-12-31 | ILA5.06 Million | ILA-9.00 Million | -1.779x | -24.10% |
| 2014-12-31 | ILA7.69 Million | ILA-11.02 Million | -1.433x | -199.92% |
| 2013-12-31 | ILA21.32 Million | ILA-10.19 Million | -0.478x | -- |